Our diagnostics consultants were asked to develop an ex-US business development strategy and identify sources of non-dilutive finance for a well-financed, venture capital-funded diagnostics company.
We identified pharma companies active in the therapeutic area of interest and assessed their attractiveness as potential partners (e.g. companion diagnostics). In doing this, we identified sources of strategic equity investment from both pharma and the diagnostics industry. We assessed the feasibility of developing a future test kit from the existing LDT and identified global partners with the most appropriate technological and commercial capabilities. Our consultants developed a list of partners for the company’s current assay in Europe, Japan, China and Korea, screening each partner for strategic, infrastructure, technology and sales/marketing fit. For each potential partner, we identified key contacts and provided the client with an actionable business development roadmap.
We were subsequently asked to conduct an in-depth, systematic search for new diagnostics intellectual property in the therapeutic area of interest and other, closely aligned therapy areas. We conducted a thorough search of patent and literature databases, classifying potential biomarker and diagnostics opportunities by DNA, RNA and epigenetics. We found a number of diagnostics in-licensing opportunities which the client then pursued, helping to support the company’s leadership in the field.Back